ADVANCED ENDOMETRIAL CARCINOMA
Clinical trials for ADVANCED ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new oral drug, NKT3964, designed to break down a protein called CDK2 that helps cancer cells grow. The trial includes adults with advanced or metastatic solid tumors, such as ovarian, endometrial, breast, gastric, and lung cancers, whose disease has…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:06 UTC
-
Electric field device joins forces with cancer drugs in early trial
Disease control Recruiting nowThis early-phase study tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The goal is to find …
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
New drug combo trial hopes to tame advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called IACS-6274, given alone or with other medicines, in people with advanced solid tumors (like certain melanomas, ovarian, or uterine cancers). The main goal is to find the safest dose and understand side effects. About 54 adults will ta…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:10 UTC
-
New drug cocktail aims to slow aggressive uterine cancer
Disease control Recruiting nowThis study compares three treatment combinations for people with advanced or recurrent endometrial cancer that has specific genetic features (pMMR and TP53 mutated). Participants will receive either standard chemotherapy (carboplatin and paclitaxel) plus the immunotherapy pembrol…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
Cancer care at home: a game changer for patients?
Symptom relief Recruiting nowThis study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…
Matched conditions: ADVANCED ENDOMETRIAL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 16, 2026 22:37 UTC